Efficacy and safety of Samtropin™ recombinant human growth hormone; a double-blind randomized clinical trial
Tóm tắt
Recombinant human growth hormone (rhGH) can increase the growth rate in growth hormone deficient children (GHD). In this randomized clinical trial, we compared the efficacy and side effects of an Iranian brand; Samtropin with Norditropin. The GHD children were randomly treated either with standard dose of Samtropin or Norditropin rhGH for one year. Upstanding height, height standard deviation score (HSDS), growth velocity (GV), serum levels of insulin like growth factor-1 (IGF-1), and bone age (BA) were determined before and during one year treatment concomitant side effects of treatment. We evaluated 22 subjects; 12 on Samtropin and, 10 on Norditropin. In each group, mean age was 12 yr and 50% of them were male. The mean differences in height, HSDS, IGF-1 and BA by Norditropin before and after 12 months were 8.8 cm, 0.5, 49 ng/ml and 2.8 yr, respectively. These measures by Samtropin were 9.1 cm, 0.6, 133 ng/ml, and 1.7 yr, respectively without any significant difference. The mean of GV by Samtropin was 9.1 vs. 8.8 cm by Norditropin without significant difference. Since the efficacy of Samtropin was found to be similar to Norditropin after 12 months; we switched to use only Samtropin for the next 12 months. The mean differences in height, HSDS, GV and BA in 20 children between months 12 and 24 were 7.0 cm, 1.6, 2.1 cm/yr and 1.0 yr, respectively (P < 0.001). We also found a non-significant decrease in IGF-1 levels. No side effects were observed. We need to conduct a post marketing surveillance with a large sample size in order to confirm our findings. Registration code number in the Iranian Registry of Clinical Trials (IRCT):
IRCT1138901181414N11
.
Tài liệu tham khảo
Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, Welch K, Bryant J: Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. HTA 2010, 14: 1–256.
Juul A, Bernasconi S, Clayton PE, Kiess W, DeMuink-Keizer Schrama S: Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE): European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm Res 2002, 58: 233–241. 10.1159/000066265
GHD/MPHD - Child Growth Foundation (CGF). Available from: http://www.childgrowthfoundation.org/Default.aspx?page=ConditionsGHD Last updated: 2012-2014., GHD/MPHD - Child Growth Foundation (CGF). Available from: Last updated: 2012–2014. http://www.childgrowthfoundation.org/Default.aspx?page=ConditionsGHD
Voss LD, Mulligan J: Bullying at school: are short pupils at risk? Questionnaire study in a cohort. BMJ 2000, 320: 612–613. 10.1136/bmj.320.7235.612
Tanaka T, Cohen P, Clayton PE, Laron Z, Hintz RL, Sizonenko PC: Diagnosis and management of growth hormone deficiency in childhood and adolescence: Part 2: Growth hormone treatment in growth hormone deficient children. Growth Horm IGF Res 2002, 12: 323–341. 10.1016/S1096-6374(02)00045-X
Rosén T, Wilhelmsen L, Bengtsson BA: Altered lipid pattern explains increased cardiovascular mortality in hypopituitary patients with growth hormone deficiency. Clin Endocrinol 1998, 48: 525–526. 10.1046/j.1365-2265.1998.00473.x
Höybye C, Hilding A, Jacobsson H, Thorén M: Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab 2002, 87: 3590–3597. 10.1210/jcem.87.8.8735
Reinehr T, Kleber M, Toschke A: Small for gestational age (SGA) status is associated with metabolic syndrome in overweight children. Eur J Endocrinol 2009, 160: 579–584. 10.1530/EJE-08-0914
Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard HW, Seibel JA, Vance ML, Zimmerman D: American Association of Clinical Endocrinologists Growth Hormone Task Force: American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children–2003 update. Endocr Pract 2003, 9: 64–76. 10.4158/EP.9.1.64
Miller BS: RhGH Safety and Efficacy Update. Adv Pediatr 2011, 58: 207–241. 10.1016/j.yapd.2011.05.001
Strobl JS, Thomas MJ: Human growth hormone. Pharmacol Rev 1994, 46: 1–34.
Lee JM, Davis MM, Clark SJ, Hofer TP, Kemper AR: Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch PediatrAdolesc Med 2006, 160: 263–269. 10.1001/archpedi.160.3.263
Wilson DM, Frane J: A brief review of the use and utility of growth hormone stimulation testing in the NCGS: do we need to do provocative GH testing? Growth Horm IGF Res 2005, 15(Suppl A):S21-S25. 10.1016/j.ghir.2005.06.005
Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL: Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to 1977 National Center for Health Statistics version. Pediatrics 2002, 109: 45–60. 10.1542/peds.109.1.45
Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child 1969, 44: 291–303. 10.1136/adc.44.235.291
Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp S, Lawson M, Radovick S, Rosenthal S, Silverman L, Speiser P: Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003, 143: 415–421. 10.1067/S0022-3476(03)00246-4
Growth Hormone Research Society: Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society J Clin Endocrinol Metab 2000, 85: 3990–3993.
Lopez-Siguero J, Victoria Borras Perez M, Balser S, Khan-Boluki J: Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study. Adv Ther 2011, 28: 879–893. 10.1007/s12325-011-0063-8
Romer T, Saenger P, Peter F, Walczak M, LeBouc Y, Khan-Boluki J, Berghout A: Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of growth hormone deficient children: results of a phase III study. Horm Res 2009, 72: 359–369. 10.1159/000249164
Bercu BB, Murray FT, Frasier SD, Rudlin C, ODea LS, Brentzel J, Hanson B, Landy H: Long-term therapy with human growth hormone (Saizen®) in children with idiopathic and organic growth hormone deficiency. Endocrine 2001, 15: 43–49. 10.1385/ENDO:15:1:043
Root AW, Kemp SF, Rundle AC, Dana K, Attie KM: Effect of long- term recombinant growth hormone therapy in children – the National Cooperative Growth Study, USA, 1985–1994. J Pediatr Endocrinol Metab 1998, 11: 403–412. 10.1515/JPEM.1998.11.3.403
Coste J, Letrait M, Carel JC, Tresca JP, Chatelain P, Rochiccioli P, Chaussain JL, Job JC: Long-term results of growth hormone treatment in France in children of short stature: population, register based study. BMJ 1997, 315: 708–713. 10.1136/bmj.315.7110.708
Tanner JM, Whitehouse H, Takaishi M: Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965, II. Arch Dis Child 1966, 41: 613–635. 10.1136/adc.41.220.613
Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG: Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002, 87: 90–98. 10.1210/jcem.87.1.8150
Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L: Effect of growth hormone therapy on height in children with idiopathic short stature. Arch Pediatr Adolesc Med 2002, 156: 230–240. 10.1001/archpedi.156.3.230
European Medicines Agency-Committee for medicinal products for human use: Annex guideline: nonclinical and clinical issues on similar medicinal products containing somatropin. EMEA/CHMP/94528/05. 22 February 2006. http://www.emea.europa.eu/pdfs/human/biosimilar/9452805en.pdf., European Medicines Agency-Committee for medicinal products for human use: Annex guideline: nonclinical and clinical issues on similar medicinal products containing somatropin. EMEA/CHMP/94528/05. 22 February 2006. . http://www.emea.europa.eu/pdfs/human/biosimilar/9452805en.pdf
Kamp GA, Zwinderman AH, Van Doorn J, Hackeng W, Frölich M, Schönau E, Wit JM: Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin Endocrinol (Oxf) 2002, 57: 315–325. 10.1046/j.1365-2265.2002.01575.x
Scire G, Del Bianco C, Spadoni GL, Cianfarani S: Growth hormone therapy does not alter the insulin-like growth factor-1/insulin-like growth factor binding protein-3 molar ration in growth hormone-deficient children. J Endocrinol Invest 2008, 31: 153–158. 10.1007/BF03345582
Wacharasindhu S, Aroonparkmongkol S, Srivuthana S: Measurement of IGF-1, IGFBP-3 and free IGF-1 levels by ELISA in growth hormone (GH) deficient children before and after GH replacement. Asian Pac J Allergy Immunol 2002, 20: 155–160.
Allen DB: Growth hormone therapy for short stature: is the benefit worth the burden? Pediatrics 2006, 118: 343–348. 10.1542/peds.2006-0329
Lippe MB, Van Herle AJ, La Franchi SH, Uller PP, Lavin N, Kaplan SA: Reversible hypothyroidism in growth hormone-deficient children treated with human growth hormone. J Clin Endocrinol Metab 1975, 40: 612–618. 10.1210/jcem-40-4-612
Root AW, Snyder PJ, Revzani I, Digforce AM, Utiger RD: Inhibition of thyrotropin-releasing hormone mediated secretion of thyrotropin by human growth hormone. J Clin Endocrinol Metab 1973, 36: 103–107. 10.1210/jcem-36-1-103
Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV: Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995, 126: 996–999. 10.1016/S0022-3476(95)70232-6
Aman J, Rosberg S, AJbertsson-Wikland K: Effect of growth hormone treatment on insulin secretion and glucose metabolism in prepubertal boys with short stature. Eur J Endocrinol 1994, 131: 246–250. 10.1530/eje.0.1310246
Soliman AT, AbdulKhadir MM: Growth parameters and predictors of growth in short children with and without growth hormone (GH) deficiency treated with human GH: a randomized controlled study. J Trop Pediatr 1996, 42: 281–286. 10.1093/tropej/42.5.281
EMEA: NutropinAq®: European Public Assessment Report (scientific discussion, 16.07.2008).http://www.emea.europa.eu/humandocs/PDFs/EPAR/nutropinaq/437400en6.pdf. Zuletzt geprüft: 28 October 2008., EMEA: NutropinAq®: European Public Assessment Report (scientific discussion, 16.07.2008). Zuletzt geprüft: 28 October 2008. http://www.emea.europa.eu/humandocs/PDFs/EPAR/nutropinaq/437400en6.pdf
Rougeot C, Marchand P, Dray F, Girard F, Job JC, Pierson M, Ponte C, Rochiccioli P, Rappaport R: Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm Res 1991, 35: 76–81. 10.1159/000181877
Zeisel HJ, Lutz A, von Petrykowski W: Immunogenicity of a mammalian cell-derived recombinant human growth hormone preparation during long-term treatment. Horm Res 1992, 37(Suppl 2):47–55. 10.1159/000182380